secwatch.observer — SEC 8-K summary
======================================

Issuer:     Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
CIK:        0001757499
Form:       8-K
Filed at:   2025-11-21T23:59:59+00:00
Accession:  0001493152-25-024618
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 1.01, 1.02, 2.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Shuttle Pharma discontinues Ropidoxuridine trial, settles $557K debt for $300K
------------------------------------------------------------------------------

- Settlement with Theradex: $300K payment in full for ~$557K debt; both parties release claims.
- Company discontinues clinical trials of Ropidoxuridine; ends enrollment and begins FDA-compliant winddown.
- Additional ~$750K owed to five hospital research sites under separate agreements.
- Expects majority of winddown costs in Q4 2025; amount still being assessed.
- Interim CEO Christopher Cooper signs filing; trial termination follows Theradex's Oct 15 termination notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/0001493152-25-024618-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1757499/000149315225024618/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-024618

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer